Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH) [Phase 3]

View source ↗

Summary

Phase 3 trial update for an oral BAY63-2521 in patients with pulmonary arterial hypertension (PAH) has completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension
• Pulmonary Hypertension

Drugs mentioned

• BAY63-2521

Snippet

Sponsor: Bayer | Conditions: Pulmonary Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2014-02-26